

Richard Bedlack

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9415428/publications.pdf>

Version: 2024-02-01

19
papers

210
citations

1307594

7
h-index

1058476

14
g-index

19
all docs

19
docs citations

19
times ranked

266
citing authors

#	ARTICLE	IF	CITATIONS
1	ALSUntangled #63: ketogenic diets. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2023, 24, 159-163.	1.7	3
2	ALSUntangled #64: butyrates. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 638-643.	1.7	6
3	Total serum immunoglobulin A in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 61-65.	1.7	3
4	Engaging ALS patients and caregivers (the ALS research ambassadors) to help design the REFINE-ALS biomarker study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 147-150.	1.7	2
5	ALSUntangled 59: Tamoxifen. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 595-598.	1.7	1
6	Recruitment of Patients With Amyotrophic Lateral Sclerosis for Clinical Trials and Epidemiological Studies: Descriptive Study of the National ALS Registry's Research Notification Mechanism. Journal of Medical Internet Research, 2021, 23, e28021.	4.3	4
7	ALSUntangled #60: light therapy. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, , 1-5.	1.7	0
8	Novel STMN2 Variant Linked to Amyotrophic Lateral Sclerosis Risk and Clinical Phenotype. Frontiers in Aging Neuroscience, 2021, 13, 658226.	3.4	38
9	ALSUntangled #62: vitamin C. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, , 1-4.	1.7	1
10	<scp>COVID</scp>â€19â€“accelerated disease progression in two patients with amyotrophic lateral sclerosis. Muscle and Nerve, 2021, 64, E13-E15.	2.2	12
11	Accessing Investigational Products Outside of a Trial: Considerations for Neuromuscular Providers. Current Treatment Options in Neurology, 2021, 23, 1.	1.8	0
12	MN-166 (ibudilast) in amyotrophic lateral sclerosis in a Phase IIb/III study: COMBAT-ALS study design. Neurodegenerative Disease Management, 2021, 11, 431-443.	2.2	16
13	ALS clinical research learning institutes (ALS-CRLI): empowering people with ALS to be research ambassadors. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 216-221.	1.7	5
14	Lunasin does not slow ALS progression: results of an open-label, single-center, hybrid-virtual 12-month trial. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 285-293.	1.7	15
15	ALSUntangled 46: penicillin G/hydrocortisone. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2019, 20, 126-131.	1.7	2
16	ALSUntangled 44: curcumin. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 623-629.	1.7	9
17	ALSUntangled 42: Elysium health's â€œbasisâ€€. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 317-319.	1.7	2
18	Palliative Care Issues in Amyotrophic Lateral Sclerosis. American Journal of Hospice and Palliative Medicine, 2016, 33, 84-92.	1.4	41

#	ARTICLE	IF	CITATIONS
19	How to handle myasthenic crisis. Postgraduate Medicine, 2000, 107, 211-222.	2.0	50